Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women between 25 and 55 years of age
• Women who are not able to become pregnant — either because they have had a permanent sterilisation procedure (such as removal of the uterus or ovaries, or tubes being blocked) or have been through menopause for at least one year before screening
• Women who could become pregnant may still be considered, provided a pregnancy test at the start of the study is negative and an approved method of contraception is used throughout — acceptable methods include hormonal contraceptives (such as the pill, patch, ring, injection, or implant, used for at least 3 months), double-barrier methods, intrauterine devices, a vasectomised sole partner with confirmed surgical success, abstinence, or a non-heterosexual lifestyle (or use of contraception if that changes)
• People with a confirmed diagnosis of CIN1 or above (shown by tissue testing) along with a positive high-risk HPV test at that time, plus a current abnormal cervical screening result and positive HPV test at screening — with more than 12 months between the earlier diagnosis and screening (confirm with trial site for exact requirements)
• Alternatively, people with documented abnormal cervical screening results (LSIL or worse) plus a positive HPV test more than 12 months ago, and a current abnormal result with positive HPV at screening
• People willing to provide copies of their cervical testing reports for eligibility review
• People willing to keep their usual lifestyle habits (diet, exercise, medications, supplements, and sleep) as consistent as possible throughout the study
• People willing to avoid MRI, CT, X-ray, or procedures involving contrast dye for 48 hours before study visits that measure nutrient levels
• People willing and able to fill in questionnaires and diaries, and to attend all required clinic visits
• People who have voluntarily given written informed consent to take part
• People who are otherwise in good health, as determined by their medical history and lab results reviewed by the trial's qualified investigator

Who may not be able to join:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the study
• People with an allergy, sensitivity, or intolerance to any ingredient in the study product or placebo
• People currently being treated for CIN, expected to need treatment during the study, who have had treatment (such as a cone biopsy or LEEP procedure) in the past five years, or who currently have CIN 3
• People with other existing conditions affecting the uterus
• People who have had a hysterectomy or destructive treatment to the cervix
• People with cervical cancer
• People with unstable metabolic conditions or ongoing chronic illness, as assessed by the trial's qualified investigator
• People with a current or past significant condition affecting the digestive tract, as assessed by the qualified investigator
• People with unstable high blood pressure (those on a stable medication dose for at least 3 months may be considered by the qualified investigator)
• People who have had a significant heart or cardiovascular event in the past 6 months (those on stable medication with no significant event may be considered on a case-by-case basis)
• People with a current or past kidney or liver condition, as assessed by the qualified investigator — though people with a history of kidney stones who have been symptom-free for 6 months may be considered
• People with a self-reported current or pre-existing thyroid condition (those on a stable medication dose for at least 3 months may be considered by the qualified investigator)
• People who have had major surgery in the past 3 months or who have planned surgery during the study (minor surgery cases may be considered individually by the qualified investigator)
• People with a current cancer diagnosis, except for those with completely removed basal cell skin cancer with no further treatment needed and a clear follow-up, or those who have been in full cancer remission for more than five years
• People with an autoimmune disease or a weakened immune system
• People with a self-reported diagnosis of HIV, Hepatitis B, or Hepatitis C, as assessed by the qualified investigator
• People with self-reported blood or bleeding disorders, as assessed by the qualified investigator
• People who drink an average of more than 2 standard alcoholic drinks per day, as assessed by the qualified investigator
• People with a history of alcohol or drug misuse in the past 12 months
• People currently using certain prescription or over-the-counter medications, supplements, or foods or drinks that may affect how the study product works or its safety (confirm with trial site for specific details)
• People with significantly abnormal laboratory results at screening, as assessed by the qualified investigator
• People who have donated blood in the 30 days before the study starts, or who plan to donate blood within 30 days of the last study visit
• People who have taken part in another clinical study within 30 days before the study starts
• People who are unable to give informed consent or have cognitive impairment that would prevent participation
• People with any other health condition or lifestyle factor that the qualified investigator believes could affect their ability to complete the study safely

Important: Always verify eligibility with the trial site directly before applying.